In specialty pharma companies with licensing deals, milestone payments, or royalty income alongside product sales, lumpy non-recurring revenue items can dramatically distort consolidated YoY growth rates. A quarter with strong underlying product growth can appear to decelerate severely if a large prior-period license payment creates a tough comparison — or appear to accelerate if a milestone lands in the current period. Stripping out non-product revenue and computing product-only growth rates is mandatory to assess true commercial momentum; the consolidated headline number is structurally unreliable.
For any pharma company with licensing, royalty, or partnership revenue: always decompose consolidated revenue into product revenue vs. non-product revenue before computing YoY growth. Build a product-only revenue series as the primary growth metric. Flag quarters where non-product revenue exceeds 10% of consolidated total — these are high-distortion quarters. The same issue applies in the opposite direction: a milestone-heavy quarter can inflate consolidated growth and create a tough comp that makes the next quarter look like deceleration. This pattern is structurally distinct from channel loading (ARQT insight) — mechanism differs but analytical discipline is the same: always identify the clean underlying signal.